摘要
目的:观察阿托伐他汀治疗非瓣膜病阵发性心房颤动的效果。方法:76例非瓣膜病阵发性心房颤动患者,随机分为治疗组(阿托伐他汀加胺碘酮,37例)及对照组(单用胺碘酮,39例),观察6个月,比较两组的C反应蛋白(CRP)水平、复发率及不良反应。结果:治疗组的CRP水平较对照组明显减少[(18.31±5.09)ng/ml∶(33.28±6.43)ng/ml,P<0.05]。治疗组复发率24.3%(9/37),显著低于对照组的48.7%(19/39),P<0.05。结论:阿托伐他汀可抑制炎症反应,减少阵发性房颤的复发。
Objective： To observe the therapeutic effect of atorvastatin on paroxysmal atrial fibrillation in patients with nonvalvular disease. Methods： The 76 patients with nonvalvular disease complicated with paroxysmal atrial fibrillation were randomly divided into two groups： treatment group [37 cases, treated by atorvastatin （20mg/d） combined with amiodarone]; control group （39 cases, treated by amiodarone only）. A treatment course was six months for two groups. The C reactive protein （CRP） and the rate of recrudescence, adverse reaction in both groups were observed. Results： The recrudescence rates were 24.3% （9/37） in treatment group, it was significantly decreased, than that of control group 48.7% （19/39）, P〈0.05. The CRP level significantly devreased in treatment group than that in control group [ （18.31±5.09） ng/ml vs. （33.28±6.43） ng/ml P〈0.05]. Conclusion： Atorvastatin can inhibit inflammation and reduce the recrudescence of paroxysmal atrial fibrillation in patients with nonvalvular disease.
出处
《心血管康复医学杂志》
CAS
2010年第4期432-434,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
